002437 誉衡药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)6.9747.308-16.5272.40823.760
总资产报酬率 ROA (%)4.1713.330-6.6440.9787.324
投入资产回报率 ROIC (%)5.5564.312-8.5251.29113.553

边际利润分析
销售毛利率 (%)54.03258.38956.92557.52874.042
营业利润率 (%)12.5496.666-8.6903.04918.957
息税前利润/营业总收入 (%)12.6287.924-7.1735.00021.367
净利润/营业总收入 (%)10.7694.901-9.3151.71213.378

收益指标分析
经营活动净收益/利润总额(%)73.84377.354-22.98754.757-29.641
价值变动净收益/利润总额(%)-3.167-23.40499.959-10.831144.225
营业外收支净额/利润总额(%)-0.1290.979-0.151-11.540-2.477

偿债能力分析
流动比率 (X)1.0430.8170.7770.8220.703
速动比率 (X)0.8220.6820.6860.6900.557
资产负债率 (%)31.65845.74958.18757.85257.201
带息债务/全部投入资本 (%)7.04429.49847.66147.104--
股东权益/带息债务 (%)1,300.139234.766107.551110.091128.478
股东权益/负债合计 (%)213.757115.22368.81069.73771.466
利息保障倍数 (X)133.3066.646-4.7692.2067.449

营运能力分析
应收账款周转天数 (天)29.71129.73726.27331.9020.000
存货周转天数 (天)60.27966.68276.13197.4260.000